抗菌药物耐药领导组在革兰阳性细菌感染研究中的优先事项与进展:叙述性综述
抗菌药物耐药领导组(ARLG)将革兰阳性细菌感染列为核心重点领域之一,其革兰阳性委员会围绕三大研究优先方向开展研究。本文总结ARLG在革兰阳性细菌感染研究中的成果,涵盖万古霉素给药优化、达巴万星在MRSA血流感染中的作用、肠球菌血流感染特征、儿童社区获得性肺炎短疗程治疗、临床试验生活质量量表开发及微生物组研究,并指出未来将聚焦可能改变难治性感染临床实践的干预性临床试验。
要点
- ARLG将革兰阳性细菌感染研究聚焦于三大优先方向:治疗策略、新型药物疗效及给药方案优化。
- 已开展研究涵盖万古霉素给药优化、达巴万星用于MRSA血流感染及肠球菌血流感染特征描述。
- 未来研究将采用创新方法学,重点开展可能改变难治性感染临床实践的干预性临床试验。
核心结论
- ARLG在革兰阳性细菌感染研究方面已取得多项进展,未来将聚焦于可能改变难治性感染(如MRSA血流感染)临床实践的干预性临床试验。
研究设计与样本
- 本文为叙述性综述,总结抗菌药物耐药领导组(ARLG)革兰阳性委员会围绕三大研究优先方向所开展的研究成果。
主要发现
- ARLG革兰阳性委员会聚焦三大优先方向:革兰阳性菌感染的治疗策略或疗法研究、MRSA与耐万古霉素肠球菌新型药物疗效评价、革兰阳性菌感染抗菌药物给药与疗程优化。
- 已总结的成果包括:优化万古霉素给药、确定达巴万星在MRSA血流感染中的作用、描述肠球菌血流感染特征、证明儿童社区获得性肺炎短疗程治疗的获益、开发用于临床试验的生活质量量表、推进对微生物组的理解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.
引用
- Doernberg SB, Arias CA, Altman DR, et al. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clin Infect Dis. 2023. PMID: 37843115. doi:10.1093/cid/ciad565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。